BALTIMORE--(BUSINESS WIRE)--Dec. 8, 2005--Osiris Therapeutics, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin enrollment in a Phase II clinical trial to evaluate the safety and effectiveness of PROCHYMAL(TM) for the treatment of Crohn’s Disease. With the launch of this program, Osiris now has five active clinical trials evaluating its proprietary stem cell drugs in autoimmune, oncology, cardiac and orthopedic indications.